Document is current
Any future updates will be listed below
-
Authors
Sogabe, Kimiko
Nakamura, Shingen https://orcid.org/0000-0001-5465-2758
Higa, Yoshiki
Miki, Hirokazu
Oda, Asuka
Maruhashi, Tomoko
Sumitani, Ryohei
Oura, Masahiro
Takahashi, Mamiko
Nakamura, Masafumi
Maeda, Yusaku
Hara, Tomoyo
Yamagami, Hiroki
Fujii, Shiro
Kagawa, Kumiko
Ozaki, Shuji
Kurahashi, Kiyoe
Endo, Itsuro
Aihara, Ken-ichi
Nakaue, Emiko
Hiasa, Masahiro
Teramachi, Jumpei
Harada, Takeshi
Abe, Masahiro
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (JP22K08455, JP21H0311, JP22K19626, JP17H05104, JP19K22719, JP23H03101)
the Research Clusters program of Tokushima University (2202003)
Japanese Society of Hematology
Myeloma patients and families
Myeloma patietns and families
- License Information
-
More Information
Article History
Received: 12 August 2023
Revised: 25 December 2023
Accepted: 27 December 2023
First Online: 21 January 2024
Declarations
:
: T.H. received research funding from GlaxoSmithKline. M.A. received research funding from Chugai Pharmaceutical, Sanofi K.K., Pfizer Seiyaku K.K., Kyowa Hakko Kirin, Janssen Pharma K.K., Takeda Pharmaceutical, Teijin Pharma, and Ono Pharmaceutical, and honoraria from Daiichi Sankyo Company. The other authors declare no competing financial interests.
